Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab, Lenalidomide, and Standard Immunochemotherapy Followed by ASCT in Relapsed/Refractory DLBCL
NCT07621406Phase 2Active, not recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab, lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Soochow University. Started Jan 2026; status: active, not recruiting.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07621406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621406.